164 related articles for article (PubMed ID: 28553733)
1. Tg.rasH2 Mice and not CByB6F1 Mice Should Be Used for 28-Day Dose Range Finding Studies Prior to 26-Week Tg.rasH2 Carcinogenicity Studies.
Paranjpe MG; Belich J; Vidmar TJ; Elbekai RH; McKeon M; Brown C
Int J Toxicol; 2017; 36(4):287-292. PubMed ID: 28553733
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies.
Paranjpe MG; Denton MD; Vidmar TJ; Elbekai RH
Toxicol Pathol; 2015 Jul; 43(5):611-20. PubMed ID: 25391312
[TBL] [Abstract][Full Text] [Related]
3. A Proposal for New Strategies in Dose Selection for 26-Week Tg.Rash2 Carcinogenicity Studies.
Paranjpe MG; Vidmar TJ; Denton MD; Elbekai RH; Mann PC; Mckeon M; Brown C; Martineck J
Int J Toxicol; 2021; 40(4):311-321. PubMed ID: 33783262
[TBL] [Abstract][Full Text] [Related]
4. Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose in Future Studies. A Response to the Counterpoints.
Paranjpe MG; Denton MD; Vidmar TJ; Elbekai RH
Toxicol Pathol; 2016 Jan; 44(1):5-8. PubMed ID: 26578636
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 Mice.
Kim TW; Papagiannis CN; Zwick LS; Engelhardt JA; Hoffmaster CM; Post NM; Matson JE; Hsiao JA; Burel SA; Henry SP
Toxicol Pathol; 2019 Jan; 47(1):82-92. PubMed ID: 30585133
[TBL] [Abstract][Full Text] [Related]
6. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Spontaneous Tumors in Tg.rasH2 Mice in 26-week Carcinogenicity Studies Conducted at a Single Test Facility during 2004 to 2012 and 2013 to 2018.
Paranjpe MG; Belich JL; Mann PC; McKeon ME; Elbekai RH; Brown CM; Patrick DJ
Toxicol Pathol; 2019 Jan; 47(1):18-25. PubMed ID: 30407148
[TBL] [Abstract][Full Text] [Related]
8. Trend analysis of body weight parameters, mortality, and incidence of spontaneous tumors in Tg.rasH2 mice.
Paranjpe MG; Denton MD; Vidmar T; Elbekai RH
Int J Toxicol; 2014; 33(6):475-81. PubMed ID: 25260361
[TBL] [Abstract][Full Text] [Related]
9. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
10. Regulatory Forum Commentary* Counterpoint: Dose Selection for Tg.rasH2 Mouse Carcinogenicity Studies.
Darbes J; Sistare FD; DeGeorge JJ
Toxicol Pathol; 2015 Jul; 43(5):621-7. PubMed ID: 26047967
[TBL] [Abstract][Full Text] [Related]
11. Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.
Suguro M; Numano T; Kawabe M; Doi Y; Imai N; Mera Y; Tamano S
Toxicol Pathol; 2017 Apr; 45(3):427-434. PubMed ID: 28421967
[TBL] [Abstract][Full Text] [Related]
12. The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups.
Paranjpe MG; Denton MD; Elbekai RH
Toxicol Pathol; 2014 Oct; 42(7):1153-7. PubMed ID: 23960167
[TBL] [Abstract][Full Text] [Related]
13. Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice.
Paranjpe MG; Elbekaei RH; Shah SA; Hickman M; Wenk ML; Zahalka EA
Int J Toxicol; 2013; 32(1):48-57. PubMed ID: 23324159
[TBL] [Abstract][Full Text] [Related]
14. Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice.
Torii M; Itoh F; Yabuuchi K; Ohno K; Kominami G; Hirano K; Tasaki T; Nara H
J Toxicol Sci; 2001 May; 26(2):61-73. PubMed ID: 11429969
[TBL] [Abstract][Full Text] [Related]
15. Di(2-ethylhexyl)phthalate induces hepatocellular adenoma in transgenic mice carrying a human prototype c-Ha-ras gene in a 26-week carcinogenicity study.
Toyosawa K; Okimoto K; Kobayashi I; Kijima K; Kikawa E; Kohchi M; Koujitani T; Tanaka K; Matsuoka N
Toxicol Pathol; 2001; 29(4):458-66. PubMed ID: 11560251
[TBL] [Abstract][Full Text] [Related]
16. Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice.
Urano K; Suzuki S; Machida K; Eguchi N; Sawa N; Kikuchi K; Hattori Y; Usui T
J Toxicol Sci; 2007 Oct; 32(4):367-75. PubMed ID: 17965551
[TBL] [Abstract][Full Text] [Related]
17. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
[TBL] [Abstract][Full Text] [Related]
18. Carcinogenicity and testicular toxicity of 2-bromopropane in a 26-week inhalation study using the rasH2 mouse model.
Goto Y; Saito A; Takanobu K; Senoh H; Saito M; Umeda Y; Yamano S
Sci Rep; 2023 Jan; 13(1):1782. PubMed ID: 36721063
[TBL] [Abstract][Full Text] [Related]
19. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Forum Commentary* Counterpoint: Dose Selection for rasH2 Mouse Carcinogenicity Studies.
Nambiar PR; Morton D
Toxicol Pathol; 2015 Jul; 43(5):628-32. PubMed ID: 25903268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
